Chapter 2

Moat and Rivals

Doximity's advantage is real and shows up in the numbers: it reaches more than 85% of U.S. physicians, earns an 89% gross margin, and runs a 33% GAAP operating margin — no competitor for pharmaceutical marketing budgets comes close on reach or profitability [1] [2]. The slowdown that halved the share price is showing up at those competitors too, which points more to a soft pharmaceutical-advertising cycle than to Doximity losing ground. The sharper question is a newer one: whether AI-native rivals reaching physicians directly erode the engagement the whole model rests on.

The moat, in numbers

A moat has to appear as returns, margins, retention, or pricing power, or it is only a story. Doximity's does. Its network reaches more than 85% of U.S. physicians across every specialty, roughly 90% of graduating medical students, and two-thirds of nurse practitioners and physician assistants — a position no rival approaches [3]. That reach is the input to the economics a pharmaceutical marketer actually pays for: a verified, near-complete audience of prescribers that is otherwise expensive and slow to assemble. Doximity argues the underlying data set — member interactions combined with previously siloed public records — "would be highly challenging and time-consuming for any competitor to replicate" [4].

The clearest evidence the advantage is company-specific rather than a good industry is the gap in profitability between Doximity and the companies chasing the same budgets. The corpus's designated peers were selected precisely because they compete for pharmaceutical and health-system marketing, hiring, or intelligence spend. On the most recently reported full year, Doximity earned a 33% operating margin; the nearest pure point-of-care marketing peer, OptimizeRx, is one-sixth its size and just crossed into profitability, while Definitive Healthcare — selling commercial intelligence into the same pharmaceutical budgets — is shrinking and lossmaking.

Sources: revenue and operating income as reported in each company's latest Form 10-K (Doximity FY2026 [5]; OptimizeRx, Phreesia, Definitive Healthcare figures per company filings). Definitive Healthcare's FY2025 operating margin reflects large goodwill impairments; its underlying operations run near breakeven. OptimizeRx guidance from its Q1 FY2026 call [6].

Phreesia is the one peer growing faster than Doximity with more scale, but most of its revenue is patient-intake software and payments rather than pharmaceutical marketing, so it is a partial comparison at best. The pattern that matters is the profitability gap: Doximity converts its audience into roughly $317 million of free cash flow at a 49% margin, while the companies competing for the same marketing dollars mostly operate at or below breakeven [7]. Pricing power of that magnitude is the signature of a wide moat, not a narrow one.

The slowdown is the cycle's, not Doximity's alone

The evidence for the through-line's central tension — structural maturing versus cyclical trough — is clearest when Doximity's slowdown is read against its peers rather than in isolation. Management's account is that demand, not the platform, is soft: it describes the market for digital pharmaceutical advertising to healthcare professionals as weak, with policy uncertainty elevated and macroeconomic risk rising, and expects the overall market to grow "at or below 5%" this year [8]. That framing is self-serving by nature — a slowing company prefers a cyclical story to a structural one — so it is worth testing against companies with no reason to coordinate their message.

They corroborate it. OptimizeRx, reporting for the calendar quarter that overlaps Doximity's, cut its full-year 2026 revenue guidance to $95–100 million — a decline from $109 million — and named the same forces: "ongoing softness in our contracted revenue base," "more cautious budget allocations, shorter contract durations," driven by "Most Favored Nation pricing dynamics and other macroeconomic factors" [9] [10]. Doximity's own commentary points to the identical mechanism — shorter contract durations and less budget visibility, which an analyst on the call flagged as "a theme with some others that have reported" [11] — and adds that where dollars do free up, brand managers now want either innovation or low-cost options [12]. Definitive Healthcare's outright revenue decline says the same thing from a third vantage point. When three independent companies selling into pharmaceutical commercial budgets all soften at once and cite the same drug-pricing-policy shock, the simplest reading is a cyclical air pocket in the buyers' budgets, not the erosion of any one seller's position.

Two facts sit on the other side of that read. First, the aggregate pharmaceutical digital-advertising market is not shrinking — industry trackers put 2026 healthcare digital ad spend around $26 billion and growing, with digital overtaking linear television — even as certain HCP channels such as digital display and social see usage pull back. A market that is growing in total while Doximity's growth falls to 4% is consistent with either a temporary budget freeze or a slow loss of share; the aggregate figure alone does not decide it. Second, and more telling, is what Doximity says about its own base: engagement is "at record levels," and revenue and engagement are each "up more than 50%" versus three years ago [13]. Rising engagement alongside falling revenue growth is the fingerprint of a demand-side problem — buyers pulling back — rather than a supply-side one where the audience itself is leaving.

Where the moat is genuinely tested

The durable threat is not the incumbents Doximity has already out-executed — Medscape and WebMD on the marketing side, the staffing firms on hiring, Zoom, Microsoft Teams, Teladoc and American Well on workflow, all of which it names and none of which has dented its economics [14]. It is the AI-native entrants the same filing lists almost in passing: "newer companies like OpenEvidence," and, on the clinical-tools side, Abridge, OpenAI and Anthropic [15].

OpenEvidence is the one to watch, because it attacks the moat at its root — physician attention — and monetizes it the same way Doximity does. It is a clinical-answer tool that, by outside accounts, roughly 65% of U.S. physicians now use, and it sells pharmaceutical advertising against those queries; research firm Sacra estimates it reached about $150 million of annualized revenue in 2025, up from under $10 million a year earlier, and it raised capital in January 2026 at a reported $12 billion valuation — nearly three times Doximity's current market value (CNBC; Sacra). If a rival can assemble comparable physician reach in a few years and rent it to the same drug makers, the premise that Doximity's audience "would be highly challenging and time-consuming to replicate" weakens.

The counter-case is specific, not reassuring boilerplate. OpenEvidence is a point-of-answer decision-support product, not a professional network with profiles, messaging, hiring, scheduling and telehealth woven into a physician's week; the switching cost that matters is the workflow embedment, and there Doximity is far ahead — its Clinical AI Suite has been reviewed and adopted by more than 140 health systems through their privacy and AI-governance committees, an enterprise trust that takes years to earn [16]. Doximity is also building on the same ground rather than ceding it, with its own clinical assistant, Ask (formerly DoxGPT), and a commercial "AI Search" advertising product launched in late April 2026 [17]. But this is the front on which the moat is contested, and it did not exist at scale two years ago.

The read, and what would change it

The measured conclusion is a wide moat on the supply side — the physician audience and the economics it produces — meeting a demand side that is cyclically soft today and structurally uncertain tomorrow. The evidence that the current slowdown is the pharmaceutical-advertising cycle rather than Doximity's decline is reasonably strong: three unrelated peers soften together, cite the same policy shock, and Doximity's own engagement keeps rising while its revenue growth falls. The strongest fact against a fully cyclical read is that the aggregate market is still growing even as Doximity's growth collapses to 4%, and that a well-funded, AI-native competitor is now reaching physicians at a pace no prior rival managed.

What would change the read, in either direction, is observable. If net revenue retention — which has fallen to 109% [18] — stabilizes and then turns up as policy uncertainty clears, the cyclical case is confirmed and the moat holds. If engagement or retention keeps sliding while competitors' physician reach and pharmaceutical-ad revenue climb, the structural case gains, and the 4% guide starts to look like a rate rather than a trough. Those two lines — Doximity's retention and engagement against the AI entrants' scale — are the ones worth watching over the next several quarters.